Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Holding UTHR?
Track your performance easily
UTHR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$208.62 - $330.00
Previous Close$327.26
Volume405.17K
Average Volume (3M)575.80K
Market Cap
$14.26B
Enterprise Value$12.23B
Total Cash (Recent Filing)$2.99B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)15.5
Beta0.20
Next Earnings
Jul 31, 2024EPS Estimate
$6.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)21.15
Shares Outstanding44,355,694
10 Day Avg. Volume766,090
30 Day Avg. Volume575,802
Standard Deviation0.10
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.34
Price to Sales (P/S)22.80
Price to Cash Flow (P/CF)23.30
P/FCF Ratio42.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.25
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda9.01
Forecast
1Y Price Target
$325.55Price Target Upside-0.52% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
United Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Ph. III TETON 2 study of Tyvaso in IPF reached full enrollment, with topline data expected.
Market PositionTyvaso is the most prescribed prostacyclin in the US, and there is no expected near-term erosion in Tyvaso's market share.
Revenue PerformanceUnited Therapeutics' 1Q24 total revenues of ~$678M were approximately 8% to 9% above consensus estimates, representing the 4th consecutive revenue beat quarter driven by growth across UTHR's base business.
Bears Say
Investor SentimentInvestor sentiment continues to be bearish on the name in light of uncertainty around competition.
Portfolio GapsNumerous portfolio gaps are looming with Tyvaso nebulizer LOE in 2026, Orenitram LOE in 2027 and competition to Tyvaso DPI from other branded alternatives.
Product CompetitionA large percentage of survey respondents expect Winrevair to meaningfully reduce use of infused and oral prostacyclins, a potential headwind for United’s Remodulin and Orenitram.
---
Ownership Overview
13.66% Insiders
29.43% Mutual Funds
30.19% Other Institutional Investors
26.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $208.62 and its highest was $330.00 in the past 12 months.
What is United Therapeutics’s market cap?
Currently, no data Available
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is 142 days ago.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on May 01, 2024. The company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.706 by $0.464.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Overvalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is $6.42.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 44,366,493 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $6.17 in its last earnings report, beating expectations of $5.706. Following the earnings report the stock price went up 8.881%.
Which hedge fund is a major shareholder of United Therapeutics?
Among the largest hedge funds holding United Therapeutics’s share is Polaris Capital Management LLC. It holds United Therapeutics’s shares valued at 30M.
---
United Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$325.55 (-0.52% Downside)
$325.55 (-0.52% Downside)
Blogger Sentiment
Bullish
UTHR Sentiment 81%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 460.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 22.0%
Last 30 Days ▲ 22.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.78%
12-Months-Change
Fundamentals
Return on Equity
20.08%
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTHR Company Deck
---
UTHR Earnings Call
Q1 2024
0:00 / 0:00
---
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTHR Stock 12 Month Forecast
Average Price Target
$325.55
▼(-0.52% Downside)
Technical Analysis
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+22.79%
reiterated a buy rating 12 months ago
Copying Eun Yang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +22.79% per trade.
---